This study demonstrates that in patients with advanced breast cancer undergoing primary chemotherapy, FDG-PET differentiates responders from nonresponders early in the course of therapy. This may help improve patient management by avoiding ineffective chemotherapy and supporting the decision to continue dose-intensive preoperative chemotherapy in responding patients.

Eleven patients suffering from chronic disabling tinnitus underwent an FDG-PET study (positron emission tomography with [¹⁸F]deoxyglucose). Nine tinnitus patients revealed a significantly increased metabolic activity in the left, 1 in the right primary auditory cortex (PAC, Brodmann area 41). These results were statistically significant when compared to 14 healthy control individuals without tinnitus. A negative result was obtained from a chronic tinnitus patient but who had no subjective complaints during the period of PET investigation. One patient was first investigated during a disabling tinnitus period, later during a period with tinnitus relief and again when suffering from severe tinnitus. The metabolic activity of his left PAC was in good accordance with the subjective degree of tinnitus complaints present during each PET investigation. Although for the first time these results give objective evidence of tinnitus sensation and localization, they are difficult to interpret because of the limited research data available that combine functional brain imaging and acoustic stimuli.

PET imaging allowed accurate differentiation between benign and malignant breast tumors providing a high specificity. Sensitivity for detection of small breast cancer ( < 1 cm) was limited due to partial volume effects. Quantitative image analysis combined with partial volume correction may be necessary to exploit fully the diagnostic accuracy. PET imaging may be helpful as a complimentary method in a subgroup of patients with indeterminate results of conventional breast imaging.

In clinical practice, PET imaging cannot substitute for histopathologic analysis in detecting axillary lymph node metastases in breast cancer patients. PET imaging, however, improves the preoperative staging of the disease in breast cancer patients and, therefore, might alter therapeutic regimen options.